发布时间：2008年5月1日

摘要：

Cancer is the second leading cause of death by disease in the United States, exceeded only by heart disease. Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors. Pharmaceutical and biotechnology companies are investing billions of dollars to search out and develop weapons for the arsenal in the war against cancer. This TriMark Publications report provides an overview of the global market for cancer therapeutics. The examination focuses on the efforts of biotechnology companies and pharmaceutical firms to incorporate new technologies for developing anti-cancer drugs into their corporate strategies. This study examines cancer therapeutic products now on the market, as well as those currently under development that might be commercialized in the near future. Additionally, the report profiles a number of firms that are actively involved in marketing and developing of products to be used in the treatment of cancer-both large multinational corporations. The analysis also provides an overview of the disease and data on cancers by site or type. It provides incidence and mortality data for different types of the disease. In addition, the report provides a summary of each of the therapies that are being used to treat cancer.

正文目录：
1. Overview 5
1.1 Introduction 5
1.2 Goals and Objectives 6
1.3 Study, Scope and Format 6
1.4 Methodology 6
1.5 Summary of Major Findings 8

2. Introduction to the Cancer Therapeutic Market 10

3. Cancer Therapeutics Market Overview 18
3.1 Cancer Therapeutics in the Pharmaceutical and Biotech Industry 18
3.2 Business Analysis of the Cancer Market 25
3.2.1 Growth Potential 25
3.2.2 Demographics of Cancer 26
3.2.3 The Global Market for Cancer Therapies 26
3.2.3.1 European Cancer Market 28
3.2.3.2 The Environment in the U.K. for Clinical Research into New Anti-Cancer Therapies 30
3.2.3.3 The Suitability of Current U.K. and E.U. Regulatory Regimes 30
3.2.3.4 Comments on the Current E.U. Regulatory Environment 31
3.3 The Pharmaceutical Industry 32
3.4 Cancer Therapies 33
3.4.1 Market Size 33
3.5 New Product Trends 35
3.5.1 Chemotherapy 35
3.5.2 Hormone Therapy 40
3.5.3 Photodynamic Therapy and Photosensitizers 41
3.5.4 Gene Therapy 41
3.5.4.1 Tumor-Suppressor Gene Therapy 42
3.5.4.2 Immunomodulatory Gene Therapy 42
3.5.4.3 Suicide Gene Therapy 42
3.5.5 Radiation Therapy 43
3.5.6 Farnesyl Transferase Inhibitors (FTIs) 44
3.5.7 Genetic Screening 44
3.5.8 Biological Therapies 45
3.5.9 Interferons 46
3.5.10 Interleukins 46
3.5.11 Tumor Necrosis Factor (TNF) 46
3.5.12 Colony-Stimulating Factors (CSFs) 46
3.5.13 Monoclonal Antibodies (MAbs) 47
3.5.14 Cancer Vaccines 48
3.5.15 Anti-Sense Therapy 50
3.5.16 Adjuvants 50
3.5.17 Angiogenesis Inhibitors 51
3.5.18 Hyperthermia 53
3.5.19 Transplants 53
3.5.19.1 Bone Marrow Transplants 53
3.5.19.2 Stem Cell Transplants 53

4. The Disease of Cancer 56
4.1 Incidence of Cancer 56
4.1.1 U.S. Statistics 56
4.1.2 Global Statistics 58
4.2 Causes of Cancer 61
4.3 Risk Factors 62
4.3.1 Smoking 63
4.3.2 Diet 63
4.3.3 Radiation 63
4.3.4 Occupational Risks 64
4.3.5 Medicine and Infection 65
4.3.6 Environmental Pollution 65
4.3.7 Reproductive Factors 65
4.3.8 Socio-Economic Factors 65
4.4 Cancer Costs 66

5. Specific Cancers 67
5.1 Bladder Cancer 67
5.1.1 Overview of the Disease 67
5.1.2 Diagnosis and Staging 68
5.1.3 Therapy 68
5.1.4 Test for Bladder Cancer Analyzes DNA in Urine 70
5.1.5 Drugs in Development 71
5.2 Brain Cancer 71
5.2.1 Overview of the Disease 71
5.2.2 Treatment Options 72
5.3 Breast Cancer 73
5.3.1 Overview of the Disease 73
5.3.2 Therapeutic Drugs 74
5.3.3 Market Overview for Breast Cancer Therapeutics 89
5.4 Cervical Cancer 91
5.4.1 Overview of the Disease 91
5.4.2 Treatment Options 92
5.5 Colon Cancer 94
5.5.1 Overview of the Disease 94
5.5.2 Treatment Options 94
5.5.3 Market Overview for Colon Cancer Therapeutics 100
5.6 Leukemia 101
5.6.1 Overview of the Disease 101
5.6.2 Treatment Options 102
5.7 Lymphoma 108
5.7.1 Overview of the Disease 108
5.7.2 Treatment Options 108
5.8 Lung Cancer 112
5.8.1 Overview of the Disease 113
5.8.2 Treatment Options 113
5.8.3 Breakthrough Treatments for Lung Cancer 114
5.8.4 Market Overview for Lung Cancer Therapeutics 123
5.9 Ovarian Cancer 123
5.9.1 Overview of the Disease 124
5.9.2 Treatment Options 124
5.10 Prostate Cancer 132
5.10.1 Overview of the Disease 132
5.10.2 Treatment Options 132

6. Corporate Profiles 137
6.1 AstraZeneca Plc 137
6.2 Biogen Idec, Inc. 138
6.3 Bristol-Myers Squibb 139
6.4 Genentech, Inc. 140
6.5 Genta, Inc. 142
6.6 Genzyme Oncology 142
6.7 GlaxoSmithKline Plc 143
6.8 ImClone Systems, Inc. 144
6.9 Medarex 146
6.10 Millennium Pharmaceuticals, Inc. 148
6.11 Novartis AG 150
6.12 Onyx Pharmaceuticals, Inc. 153
6.13 OSI Pharmaceuticals, Inc. 154
6.14 Pfizer 155
6.15 Regeneron Pharmaceuticals, Inc. 156
6.16 Roche 157
6.17 Sanofi-Aventis 161

7. References 164
7.1 Online References for Cancer 164
7.2 Print Sources 165
7.3 Product Approvals for Cancer Indications 173

图表目录

Table 2.1: The 646 Medicines in Development for Cancer, 2006 10
Table 2.2: Drug Approvals for Cancer Indications, 1996-2007 11
Table 3.1: Opportunities for Molecular-Targeting Therapeutics for Cancer 20
Table 3.2: Top U.S. Biotechnology Companies by Market Capitalization 21
Table 3.3: Top Pharmaceutical Companies by Market Capitalization 21
Table 3.4: Clinical Development for some of Hoffman-La Roche Products 22
Table 3.5: Global Pharmaceutical Industry R&D Spending, 1995-2006 28
Table 3.6: U.S. Government NIH Research Budget, 1995-2007 28
Table 3.7: Health Spending as Percentage of GDP by Country 29
Table 3.8: Spending on Health by Country 29
Table 3.9: Annual Spending on Cancer Drugs Per Person 29
Table 3.10: Patients Per Cancer Specialist 30
Table 3.11: World Healthcare Cancer Therapeutics Markets by Region 33
Table 3.12: The Projected Growth in the U.S. Market for Cancer Therapeutics, 1998-2006 34
Table 3.13: The Projected Growth in the European Market for Cancer Therapeutics, 1998-2006 34
Table 3.14: The Projected Growth in the Japanese Market for Cancer Therapeutics, 1998-2006 34
Table 3.15: Cancer Vaccines Approved or in Phase III Clinical Trials 49
Table 3.16: Anti-Angiogenic Drugs in Clinical Trial for Cancer 51
Table 4.1: Estimates of New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2007 56
Table 4.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S., by Sex, 2007 57
Table 4.3: Estimated Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2007 58
Table 4.4: Estimated Number of New Cancer Cases and Deaths by World Area, 2007 60
Table 4.5: Cancer Death Rates per 100,000 Population (and Rank) for all Cancer Sites by Country, 2006 61
Table 4.6: Genes and Cancer Risk 62
Table 4.7: Carcinogens in the Workplace 64
Table 5.1: Drugs Used in Bladder Cancer Therapy 69
Table 5.2: Drugs in Development for Bladder Cancer 71
Table 5.3: Medicines in Development for Brain Cancer 72
Table 5.4: Classes of Chemotherapy Drugs Used to Treat Breast Cancer 74
Table 5.5: U.S. Sales of Doxorubicin, 2001-2009 76
Table 5.6: New Therapeutics for Breast Cancer 78
Table 5.7: Other Classes of Drugs Used to Treat Breast Cancer 80
Table 5.8: Worldwide AstraZeneca's Nolvadex Sales, 2000-2005 82
Table 5.9: Aromatase Inhibitors 83
Table 5.10: Worldwide Sales Estimates for Arimidex, 2000-2008 84
Table 5.11: Worldwide Herceptin Sales, 1999-2005 86
Table 5.12: Innovative Drug Therapies applied to the Breast Cancer Market Sector 89
Table 5.13: Treatment Regimens for Advanced Breast Cancer 89
Table 5.14: Medicines in Development for Cervical Cancer 93
Table 5.15: New Therapies for Colon Cancer 94
Table 5.16: Worldwide Sales for Xeloda, 2001-2005 97
Table 5.17: Worldwide Sales of Tomudex, 1998-2005 97
Table 5.18: Medicines in Development for Leukemia 103
Table 5.19: Pricing of Novartis' Gleevec in Various Strengths in the U.S. 106
Table 5.20: Medicines in Development for Lymphoma 109
Table 5.21: U.S. Sales of Rituxan, 1999-2005 111
Table 5.22: Cytotoxics for Lung Cancer Therapy 115
Table 5.23: Anti-Angiogenics for Lung Cancer 115
Table 5.24: Drugs in Development for Lung Cancer 120
Table 5.25: Current Therapies for Ovarian Cancer 124
Table 5.26: Emerging Therapies for Ovarian Cancer 125
Table 5.27: New Development Therapies for Ovarian Cancer 126
Table 5.28: New Drug Types for Ovarian Cancer 127
Table 5.29: Medicines in Development for Prostate Cancer 133
Table 6.1: Potential Therapeutic Indications and Development Stages 146
Table 6.2: Products in Clinical Development in Phase II and III (Including Additional Indications) 161
Table 7.1: Drugs Currently Approved for the Treatment of Cancer 166